Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators, Health and Human Services Secretary Robert F. Kennedy Jr. said Tuesday.

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40% share price gain in 2025.

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

The FDA has approved Moderna's new COVID-19 shot, an mRNA vaccine called mNexspike, with some limits on who can get it.

The new COVID-19 vaccine from Moderna, mNexspike, is made in a way that allows for a lower dose.

The Department of Health and Human Services (HHS) is canceling hundreds of millions of dollars in funding pledged to Moderna to help the company develop, test and license mRNA-based vaccines to com… ...

Moderna had been developing a vaccine to combat an outbreak of bird flu in dairy cattle in spring 2024, but the U.S. government is rescinding millions of dollars in funding.

Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID-19 vaccine boosters.

Why Vaccine-Maker Moderna Is Injecting AI Across the Company More than 3,000 GPTs are reportedly in use at Moderna, which has partnered with OpenAI.

Moderna Museet is one of Europes leading museums of modern and contemporary art, with an internationally prestigious collection of art from the 20th century and onwards. The collection includes key ...

In today's biotech news: Eli Lilly falls as Novo secures major insurance win, Moderna furthers spending cuts, updates vaccine plans, and more.

Just days ago, Peter Marks, a key vaccine official at the agency, resigned, sending Moderna shares lower once again. Is Moderna stock now one to avoid or a bad-news buy? Image source: Getty Images.